H型高血压患者血清中ADMA、CRP水平与患者动脉粥样硬化及心血管事件的关系

目的探讨H型高血压患者血清中不对称二甲基精氨酸(ADMA)、C反应蛋白(CRP)水平与患者动脉粥样硬化及其心血管事件的关系。方法选择2012年8月至2015年8月在该院诊断为H型高血压患者80例为研究对象,并以同期80例非H型的原发性高血压患者为对照组,采用酶联免疫吸附试验法检测患者血清中ADMA、CRP水平,采用超声检测患者颈动脉并评价动脉粥样硬化情况,对所有患者定期进行随访,记录患者心血管事件的发生,探讨ADMA、CRP水平与患者动脉粥样硬化及心血管事件的关系。结果 H型高血压患者ADMA、CRP水平以及动脉粥样硬化发生率高于对照组,差异有统计学意义(P0.05)。H型高血压患者中动脉粥样硬化37例,患者ADMA、CRP水平高于非动脉粥样硬化者,差异均有统计学意义(P0.05)。Logistic回归分析结果提示,平均动脉压、ADMA水平是患者心血管事件的独立风险因素(P0.05)。结论血清中ADMA水平与动脉粥样硬化密切相关,是H型高血压患者心血管事件的独立风险因素。

Relationship between serum levels of ADMA,CRP and atherosclerosis,cardiovascular events in patients with type H hypertension

Objective To investigate the relationship between serum levels of ADMA ,CRP and atherosclerosis ,cardiovascular e-vents in patients with type H hypertension .Methods Totally 80 patients with type H hypertension from August 2012 to August 2015 in our hospital were selected ,80 cases of non H type essential hypertension patiens were recruited as control group ,enzyme linked immunosorbent assay (ELISA) was used to detect serum levels of ADMA and CRP ,and carotid atherosclerosis was evalua-ted by ultrasonography .All patients were followed up regularly to record the occurrence of cardiovascular events ,and to investigate the relationship between ADMA and CRP levels and atherosclerosis and cardiovascular events .Results The levels of ADMA ,CRP and the rate of atherosclerosis in patients with type H hypertension were higher than those in the control group ,the difference was statistically significant (P<0 .05) .There were 37 cases of atherosclerosis in patients with type H hypertension ,and the levels of ADMA and CRP in patients with atherosclerosis were higher than those in non atherosclerosis group ,and the difference was statis-tically significant (P<0 .05) .Logistic regression analysis indicated that mean arterial pressure and ADMA levels were independent risk factors for cardiovascular events in patients (P<0 .05) .Conclusion Serum levels of ADMA are closely related to atherosclero-sis ,and are independent risk factors for cardiovascular events in patients with type H hypertension .